Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging
- PMID: 12944607
- DOI: 10.1148/radiol.2291020200
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging
Abstract
Purpose: To evaluate which parameters of dynamic magnetic resonance (MR) imaging and T2 relaxation rate would result in optimal discrimination of prostatic carcinoma from normal peripheral zone (PZ) and central gland (CG) tissues and to correlate these parameters with tumor stage, Gleason score, patient age, and tumor markers.
Materials and methods: Of 58 patients with prostatic carcinoma, 36 were included for analysis. Patients underwent MR imaging at 1.5 T with an endorectal-pelvic phased-array coil and subsequently underwent prostatectomy. A T2-weighted turbo spin-echo sequence, an intermediate-weighted sequence, and a fast T1-weighted gradient-echo sequence (seven sections in 2.03 seconds) during bolus injection of 0.1 mmol gadopentetate dimeglumine per kilogram of body weight were performed. Contrast agent concentration-time curves were obtained for prostatic carcinoma and normal PZ and CG tissue by using whole-mount sections to guide placement of regions of interest. Onset time, time to peak, peak enhancement, relative peak enhancement, washout, and T2 relaxation rates were calculated. Multivariate receiver operating characteristic analysis was performed with and without relative peak enhancement.
Results: Results of multivariate receiver operating characteristic analysis showed that relative peak enhancement demonstrated the highest area under the receiver operating characteristic curve (AUC) in the PZ and the CG (AUC = 0.93, 0.82). Results of multivariate analysis without relative peak enhancement showed that relative peak enhancement in the PZ and washout in the CG demonstrated the highest AUC (AUC = 0.9, 0.81). Pearson correlation coefficients between the dynamic parameters or T2 relaxation rates in carcinoma and the tumor stage, Gleason score, patient age, and tumor markers ranged between 0.02 and 0.44.
Conclusion: The optimal parameter for discrimination of prostatic carcinoma in the PZ and CG was relative peak enhancement. If relative peak enhancement was not used, then peak enhancement was optimal in the PZ, and washout was optimal in the CG. Poor-to-moderate correlation was present between the dynamic parameters or T2 relaxation rate in carcinoma and the tumor stage, Gleason score, patient age, tumor volume, and prostate-specific antigen.
Copyright RSNA, 2003
Comment in
-
Comments on T2 measurements of prostate tissue.Radiology. 2004 Aug;232(2):624-5; author reply 625-6. doi: 10.1148/radiol.2322032026. Radiology. 2004. PMID: 15286328 No abstract available.
Similar articles
-
Role of high-field MR in studies of localized prostate cancer.NMR Biomed. 2014 Jan;27(1):67-79. doi: 10.1002/nbm.2967. Epub 2013 May 24. NMR Biomed. 2014. PMID: 23703839 Review.
-
MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.AJR Am J Roentgenol. 2009 Dec;193(6):1583-91. doi: 10.2214/AJR.09.2540. AJR Am J Roentgenol. 2009. PMID: 19933651
-
Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.Invest Radiol. 2009 Sep;44(9):577-84. doi: 10.1097/RLI.0b013e3181b4c1fe. Invest Radiol. 2009. PMID: 19668002
-
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.AJR Am J Roentgenol. 2007 Oct;189(4):849. doi: 10.2214/AJR.06.1329. AJR Am J Roentgenol. 2007. PMID: 17885055
-
[Place of contrast imaging in prostate cancer detection].Prog Urol. 2006 Jun;16(3):275-80. Prog Urol. 2006. PMID: 16821336 Review. French.
Cited by
-
Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue.PLoS One. 2023 Jun 23;18(6):e0287651. doi: 10.1371/journal.pone.0287651. eCollection 2023. PLoS One. 2023. PMID: 37352312 Free PMC article.
-
Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol.BMJ Open. 2023 Apr 5;13(4):e070280. doi: 10.1136/bmjopen-2022-070280. BMJ Open. 2023. PMID: 37019486 Free PMC article.
-
Effects of dynamic contrast enhancement on transition zone prostate cancer in Prostate Imaging Reporting and Data System Version 2.1.Radiol Oncol. 2023 Jan 20;57(1):42-50. doi: 10.2478/raon-2023-0007. eCollection 2023 Mar 1. Radiol Oncol. 2023. PMID: 36655324 Free PMC article.
-
Role of MRI-US Fusion Biopsy in Diagnosing Prostatic Cancer.Indian J Surg Oncol. 2017 Sep;8(3):357-360. doi: 10.1007/s13193-016-0612-3. Epub 2017 Mar 2. Indian J Surg Oncol. 2017. PMID: 36118387 Free PMC article.
-
Assessment of Early Response to Lung Cancer Chemotherapy by Semiquantitative Analysis of Dynamic Contrast-Enhanced MRI.Dis Markers. 2022 Jul 23;2022:2669281. doi: 10.1155/2022/2669281. eCollection 2022. Dis Markers. 2022. PMID: 35915736 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical